The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Open accessAbstract
Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer's disease, both caused by a duplication of the amyloid-β precursor protein gene (APP; termed APP(Dp)), two with sporadic Alzheimer's disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-activated cell sorting and characterized. Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified neurons from the two APP(Dp) patients and patient sAD2 exhibited significantly higher levels of the pathological markers amyloid-β(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3β (aGSK-3β). Neurons from APP(Dp) and sAD2 patients also accumulated large RAB5-positive early endosomes compared to controls. Treatment of purified neurons with β-secretase inhibitors, but not γ-secretase inhibitors, caused significant reductions in phospho-Tau(Thr 231) and aGSK-3β levels. These results suggest a direct relationship between APP proteolytic processing, but not amyloid-β, in GSK-3β activation and tau phosphorylation in human neurons. Additionally, we observed that neurons with the genome of one sAD patient exhibited the phenotypes seen in familial Alzheimer's disease samples. More generally, we demonstrate that iPSC technology can be used to observe phenotypes relevant to Alzheimer's disease, even though it can take decades for overt disease to manifest in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“iPSC-derived neurons from individuals with AD exhibit increased production of Aβ42, active GSK-3β, phosphorylated tau, endosomal abnormalities, and oxidative stress (12–17)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but late-stage neuropathological features, such as formation of insoluble tau and neurodegeneration have not been reported.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of pTau in FAD neurons can be reversed by inhibition of β-secretase, the enzyme that converts APP to β-CTF indicating a direct relationship between APP processing and Tau (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, neuronal endosomal swelling has been classed as an early hallmark of Alzheimer's disease indicative of a perturbation in endosomal cargo sorting [8,9,56].”
From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, inhibition of γ-secretase (to prevent generation of Aβ from β-CTF) did not reduce pTau, indicating that the effect of APP processing on pTau in early AD neurons is not solely mediated by extracellular Aβ (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“pThr231Tau accumulates in APP duplication (APPdp) iPSC-derived FAD neurons (Israel et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
In the citing paper
“Several studies related to neurological disease successfully reverted a disease-associated cellular phenotype in patient-derived cells by correcting the disease-associated mutation, for example in the MAPT gene106,107.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [106]
In the citing paper
“Multiple groups have characterized iPSC lines from donor cells from FAD and sAD patients, which show increased production of Aβ, particularly Aβ42, and tau hyperphosphorylation in comparison to iPSCs derived from age-matched non-demented controls [66, 82, 101, 175].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
In the citing paper
“Some iPSC lines also have evidence of additional AD-associated pathology such as increased activation of GSK3β [66], increased number of large endosomes [66], and accumulation of intraneuronal Aβ oligomers [82].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liang, Q., Fujita, R., Yamashita, T., Angulo, S. L., Rhinn, H., Rhee, D. B., Doege, C. A., Chau, L., Aubry, L., Vanti, W. B., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.007 · Cited by 231
RetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
Cited by
Sorted by citations
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Rapid single-step induction of functional neurons from human pluripotent stem cells
Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., Marro, S., Patzke, C., Acuna, C., Covy, J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.029 · Cited by 1,644
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195
Shi, Y., Kirwan, P., & Livesey, F. J. (2012) · Nature Protocols · doi:10.1038/nprot.2012.116 · Cited by 972
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M. (2016) · Nature · doi:10.1038/nature17664 · Cited by 951
Induced Pluripotent Stem Cells: Past, Present, and Future
Yamanaka, S. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.005 · Cited by 878
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Mertens, J., Paquola, A. C. M., Ku, M., Hatch, E., Böhnke, L., Ladjevardi, S., McGrath, S., Campbell, B., Lee, H., Herdy, J. R., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.09.001 · Cited by 765
Self-citationKondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease
Park, J., Wetzel, I., Marriott, I., Dréau, D., D’Avanzo, C., Kim, D. Y., Tanzi, R. E., & Cho, H. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0175-4 · Cited by 644
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Self-citationOligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 613
Neural Stem Cells: Generating and Regenerating the Brain
Gage, F. H., & Temple, S. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.037 · Cited by 595
Self-citationRaja, W. K., Mungenast, A. E., Lin, Y.-T., Ko, T., Abdurrob, F., Seo, J., & Tsai, L.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161969 · Cited by 569
Schöndorf, D. C., Aureli, M., McAllister, F. E., Hindley, C. J., Mayer, F., Schmid, B., Sardi, S. P., Valsecchi, M., Hoffmann, S. A., Schwarz, L. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5028 · Cited by 554
Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y. S., Li, G., Walker, D., Zhang, W. R., Kreitzer, A. C., & Huang, Y. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.018 · Cited by 554
Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment
Golpich, M., Amini, E., Mohamed, Z., Raymond, A. A., Ibrahim, N. M., & Ahmadiani, A. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12655 · Cited by 555
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508
Modeling Alzheimer’s disease with iPSC-derived brain cells
Penney, J., Ralvenius, W. T., & Tsai, L.-H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0468-3 · Cited by 471
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Cerneckis, J., Cai, H., & Shi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01809-0 · Cited by 452
The multiplex model of the genetics of Alzheimer's disease
Sims, R., Hill, M., & Williams, J. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0599-5 · Cited by 466
Induced pluripotent stem cells: the new patient?
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3448 · Cited by 454
Self-citationModeling amyloid beta and tau pathology in human cerebral organoids
Gonzalez, C., Armijo, E., Bravo-Alegria, J., Becerra-Calixto, A., Mays, C. E., & Soto, C. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0229-8 · Cited by 430
Wang, C., Najm, R., Xu, Q., Jeong, D.-E., Walker, D., Balestra, M. E., Yoon, S. Y., Yuan, H., Li, G., Miller, Z. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0004-z · Cited by 428
Singh, V. K., Kalsan, M., Kumar, N., Saini, A., & Chandra, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00002 · Cited by 442
Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro
Bardy, C., van den Hurk, M., Eames, T., Marchand, C., Hernandez, R. V., Kellogg, M., Gorris, M., Galet, B., Palomares, V., Brown, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504393112 · Cited by 429
Self-citationiPS cells: a game changer for future medicine
Inoue, H., Nagata, N., Kurokawa, H., & Yamanaka, S. (2014) · The EMBO Journal · doi:10.1002/embj.201387098 · Cited by 414
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
η-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Muratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379
Zhao, J., Fu, Y., Yamazaki, Y., Ren, Y., Davis, M. D., Liu, C.-C., Lu, W., Wang, X., Chen, K., Cherukuri, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19264-0 · Cited by 374
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M. K., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2018) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 391
Long-Distance Axonal Growth from Human Induced Pluripotent Stem Cells after Spinal Cord Injury
Lu, P., Woodruff, G., Wang, Y., Graham, L., Hunt, M. A., Wu, D., Boehle, E., Ahmad, R., Poplawski, G. H. D., Brock, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.014 · Cited by 367
Self-citationOtani, T., Marchetto, M. C., Gage, F. H., Simons, B. D., & Livesey, F. J. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.03.003 · Cited by 353
Self-citationvan der Kant, R., Langness, V. F., Herrera, C. M., Williams, D. A., Fong, L. K., Leestemaker, Y., Steenvoorden, E., Rynearson, K. D., Brouwers, J. F., Helms, J. B., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.12.013 · Cited by 350
Self-citationOrgan-on-a chip systems: microengineering to biomimic living systems
Zheng, F., Fu, F., Cheng, Y., Wang, C., Zhao, Y., & Gu, Z. (2016) · Small · doi:10.1002/smll.201503208 · Cited by 338
Genetic insights in Alzheimer's disease
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70259-4 · Cited by 290
Almeida, S., Gascon, E., Tran, H., Chou, H. J., Gendron, T. F., DeGroot, S., Tapper, A. R., Sellier, C., Charlet-Berguerand, N., Karydas, A., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1149-y · Cited by 321
Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons
Chen, H., Qian, K., Du, Z., Cao, J., Petersen, A., Liu, H., Blackbourn, L. W., Huang, C.-L., Errigo, A., Yin, Y., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.004 · Cited by 318
The complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 343
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003771 · Cited by 310
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans
Saykin, A. J., Shen, L., Yao, X., Kim, S., Nho, K. T., Risacher, S. L., Ramanan, V. K., Foroud, T., Faber, K. M., Sarwar, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.009 · Cited by 307
Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience
Mertens, J., Marchetto, M. C., Bardy, C., & Gage, F. H. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.46 · Cited by 307
Self-citationKwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M. D., Fak, J. J., Olsen, O., Darnell, R. B., & Tessier‐Lavigne, M. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.010 · Cited by 327
Human cerebral organoids — a new tool for clinical neurology research
Eichmüller, O. L., & Knoblich, J. A. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00723-9 · Cited by 319
Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery
Sharma, A., Sances, S., Workman, M. J., & Svendsen, C. N. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.02.011 · Cited by 296
Blanchard, J. W., Bula, M., Davila-Velderrain, J., Akay, L. A., Zhu, L., Frank, A., Victor, M. B., Bonner, J. M., Mathys, H., Lin, Y.-T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0886-4 · Cited by 283
In vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 315
Balez, R., Steiner, N., Engel, M., Muñoz, S. S., Lum, J. S., Wu, Y., Wang, D., Vallotton, P., Sachdev, P. S., O’Connor, M. D., et al. (2016) · Scientific Reports · doi:10.1038/srep31450 · Cited by 280
A 3D human neural cell culture system for modeling Alzheimer's disease
Kim, Y. H., Choi, S. H., D'Avanzo, C., Hebisch, M., Sliwinski, C., Bylykbashi, E., Washicosky, K. J., Klee, J. B., Brüstle, O., Tanzi, R. E., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.065 · Cited by 269
Current status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 275
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., & Itinteang, T. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00021 · Cited by 277
Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256
Mertens, J., Reid, D. A., Lau, S., Kim, Y., & Gage, F. H. (2018) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031534 · Cited by 263
Self-citationCartilage tissue engineering using differentiated and purified induced pluripotent stem cells
Diekman, B. O., Christoforou, N., Willard, V. P., Sun, H., Sanchez‐Adams, J., Leong, K. W., & Guilak, F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210422109 · Cited by 265
Investigating human disease using stem cell models
Sterneckert, J. L., Reinhardt, P., & Schöler, H. R. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3764 · Cited by 262
Cellular Functions of the Amyloid Precursor Protein from Development to Dementia
van der Kant, R., & Goldstein, L. S. B. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.022 · Cited by 272
Self-citationHallmarks of Alzheimer’s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain
Espuny-Camacho, I., Arranz, A. M., Fiers, M., Snellinx, A., Ando, K., Munck, S., Bonnefont, J., Lambot, L., Corthout, N., Omodho, L., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.001 · Cited by 244
Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients
Mertens, J., Herdy, J. R., Traxler, L., Schafer, S. T., Schlachetzki, J. C. M., Böhnke, L., Reid, D. A., Lee, H., Zangwill, D., Fernandes, D. P., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.04.004 · Cited by 240
Self-citationXiao, Q., Yan, P., Ma, X., Liu, H., Perez, R., Zhu, A., Gonzales, E., Tripoli, D. L., Czerniewski, L., Ballabio, A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0705-15.2015 · Cited by 238
Retromer in Alzheimer disease, Parkinson disease and other neurological disorders
Small, S. A., & Petsko, G. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3896 · Cited by 227
iPS cell technologies: significance and applications to CNS regeneration and disease
Okano, H., & Yamanaka, S. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-22 · Cited by 236
Juopperi, T. A., Kim, W. R., Chiang, C.-H., Yu, H., Margolis, R. L., Ross, C. A., Ming, G., & Song, H. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-17 · Cited by 234
Gunhanlar, N., Shpak, G., van der Kroeg, M., Gouty‐Colomer, L., Munshi, S. T., Lendemeijer, B., Ghazvini, M., Dupont, C., Hoogendijk, W. J. G., Gribnau, J. H., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.56 · Cited by 226
Ochalek, A., Mihalik, B., Avci, H. X., Chandrasekaran, A., Téglási, A., Bock, I., Giudice, M. L., Táncos, Z., Molnár, K., László, L., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0317-z · Cited by 225
Morel, E., Chamoun, Z., Lasiecka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., Dall’Armi, C., Simoes, S., Point Du Jour, K. S., McCabe, B. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3250 · Cited by 222
Generation of integration-free neural progenitor cells from cells in human urine
Wang, L., Wang, L., Huang, W., Su, H., Xue, Y., Su, Z., Liao, B., Wang, H., Bao, X., Qin, D., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2283 · Cited by 222
Davis, O. B., Shin, H. R., Lim, C.-Y., Wu, E. Y., Kukurugya, M., Maher, C. F., Perera, R. M., Ordonez, M. P., & Zoncu, R. (2021) · Developmental Cell · doi:10.1016/j.devcel.2020.11.016 · Cited by 200
Kim, S., Sato, Y., Mohan, P. S., Peterhoff, C., Pensalfini, A., Rigoglioso, A., Jiang, Y., & Nixon, R. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.97 · Cited by 212
Statin treatment rescues FGFR3 skeletal dysplasia phenotypes
Yamashita, A., Morioka, M., Kishi, H., Kimura, T., Yahara, Y., Okada, M., Fujita, K., Sawai, H., Ikegawa, S., & Tsumaki, N. (2014) · Nature · doi:10.1038/nature13775 · Cited by 216
Park, J., Jang, S., Lee, D., Lee, J.-H., Kang, U., Chang, H., Kim, H. J., Han, S.-H., Seo, J., Choi, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20440-5 · Cited by 227
REST and neural gene network dysregulation in iPSC models of Alzheimer’s disease
Meyer, K., Feldman, H. M., Lu, T., Drake, D., Lim, E. T., Ling, K.-H., Bishop, N. A., Pan, Y., Seo, J., Lin, Y.-T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.023 · Cited by 216
Singh, R., Shen, W., Kuai, D., Martin, J. M., Guo, X., Smith, M. A., Perez, E. T., Phillips, M. J., Simonett, J. M., Wallace, K. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds469 · Cited by 225
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Taoufik, E., Kouroupi, G., Zygogianni, O., & Matsas, R. (2018) · Open Biology · doi:10.1098/rsob.180138 · Cited by 213
Herdy, J. R., Traxler, L., Agarwal, R. K., Karbacher, L., Schlachetzki, J. C. M., Boehnke, L., Zangwill, D., Galasko, D., Glass, C. K., Mertens, J., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.11.010 · Cited by 208
Self-citationUpdates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
Okano, H., & Morimoto, S. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.01.007 · Cited by 206
The paradox of syndromic diversity in Alzheimer disease
Warren, J. D., Fletcher, P. D., & Golden, H. L. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.135 · Cited by 204
A Quantitative Framework to Evaluate Modeling of Cortical Development by Neural Stem Cells
Stein, J. L., de la Torre-Ubieta, L., Tian, Y., Parikshak, N. N., Hernández, I. A., Marchetto, M. C., Baker, D. K., Lu, D., Hinman, C. R., Lowe, J. K., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.035 · Cited by 201
Self-citationRomero, I. G., Pavlovic, B. J., Hernando-Herraez, I., Zhou, X., Ward, M. C., Banovich, N. E., Kagan, C. L., Burnett, J. E., Huang, C. H., Mitrano, A., et al. (2015) · eLife · doi:10.7554/elife.07103 · Cited by 197
Self-citationPaonessa, F., Evans, L., Solanki, R., Larrieu, D., Wray, S., Hardy, J., Jackson, S. P., & Livesey, F. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.085 · Cited by 189
Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia
Brownjohn, P. W., Smith, J., Solanki, R., Lohmann, E., Houlden, H., Hardy, J., Dietmann, S., & Livesey, F. J. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.003 · Cited by 193
Lee, H.-K., Velazquez Sanchez, C., Chen, M., Morin, P. J., Wells, J. M., Hanlon, E. B., & Xia, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163072 · Cited by 190
Young, J. E., Boulanger-Weill, J., Williams, D. A., Woodruff, G., Buen, F., Revilla, A. C., Herrera, C. M., Israel, M. A., Yuan, S. H., Edland, S. D., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.004 · Cited by 189
Self-citationFunctionalization of Brain Region-specific Spheroids with Isogenic Microglia-like Cells
Song, L., Yuan, X., Jones, Z., Vied, C., Yu, M., Marzano, M., Hua, T., Sang, Q. A., Guan, J., Ma, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47444-6 · Cited by 192
Mitochondrial Dysfunction in Alzheimers Disease: Opportunities forDrug Development
Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., & Singh, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210517114016 · Cited by 209
Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function
Merkle, F. T., & Eggan, K. C. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.016 · Cited by 190
Aberrant iPSC-derived human astrocytes in Alzheimer's disease
Jones, V. C., Atkinson-Dell, R., Verkhratsky, A., & Mohamet, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.89 · Cited by 186
Janczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., Brothers, S. P., & Wahlestedt, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805436115 · Cited by 183
RetractedKnupp, A., Mishra, S., Martinez, R., Braggin, J. E., Szabo, M., Kinoshita, C., Hailey, D. W., Small, S. A., Jayadev, S., & Young, J. E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107719 · Cited by 165
APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.
Moore, S., Evans, L. D. B., Andersson, T., Portelius, E., Smith, J., Dias, T. B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.068 · Cited by 179
Xu, W. L., Weissmiller, A. M., White, J. A., Fang, F., Wang, X., Wu, Y., Pearn, M. L., Zhao, X., Sawa, M., Chen, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82409 · Cited by 180
Metadata
- Authors
- Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, F. H., Remes, A. M., Koo, E. H., & Goldstein, L. S. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Salk Institute for Biological Studies (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- BD Biosciences (United States) (US)
- University of Oulu (FI)
- Corresponding author
- Goldstein, Lawrence S. B.
- ORCID
- Venue
- Nature
- Published
- 2012-01-25
- Volume
- 482
- Issue
- 7384
- Pages
- 216-220
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3338985
- OpenAlex
- W2088714934
- Cited by
- 1,253
- References
- 37
- Citations by year
- 2026: 45 · 2025: 55 · 2024: 73 · 2023: 61 · 2022: 100 · 2021: 73 · 2020: 105 · 2019: 86 · 2018: 87 · 2017: 76 · 2016: 108 · 2015: 105 · 2014: 106 · 2013: 95 · 2012: 74
- FWCI
- 81.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- (No Title)
- Funders
- Howard Hughes Medical Institute
- National Institute on Aging (P50AG005131)
- National Institute of General Medical Sciences (T32GM008666)
- National Institute of Neurological Disorders and Stroke (P30NS047101, RC1NS068705)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD001259)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, induced pluripotent stem cells, familial Alzheimer's disease, sporadic Alzheimer's disease, amyloid-beta secretion, gamma-secretase inhibitors, beta-secretase inhibitors, phosphorylated tau, glycogen synthase kinase-3β, APP proteolytic processing, iPSC-derived neurons, patient-derived fibroblasts
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Astrocytes, Cells, Cultured, Enzyme Activation, Female, Fibroblasts, Humans, Male, Middle Aged, Models, Biological, Neurons, Peptide Fragments, Phosphoproteins, Phosphorylation, Protease Inhibitors, Endosomes, Biomarkers, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Synapsins, tau Proteins, Coculture Techniques, Glycogen Synthase Kinase 3, Amyloid Precursor Protein Secretases, Induced Pluripotent Stem Cells, Proteolysis, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
